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Docetaxel With Trastuzumab and Bevacizumab as
Neoadjuvant Therapy for HER2-Positive Locally
Advanced Breast Cancer or as Adjuvant Therapy
for HER2-Positive Pathologic Stage III Breast
Cancer: A Phase II Trial of the NSABP
Foundation Research Group, FB-5
John W. Smith, II,1,2 Marc E. Buyse,3 Priya Rastogi,1,4 Charles E. Geyer, Jr,1,5
Samuel A. Jacobs,1,4 Erica J. Patocskai,1,6 André Robidoux,1,6 Alison K. Conlin,1,7
Bilal Ansari,1,8 George P. Keogh,1,9 Philip J. Stella,1,10 Howard M. Gross,1,11
Raymond S. Lord,1,12 Jonathan A. Polikoff,1,13 Celine Mauquoi,3
Eleftherios P. Mamounas,1,14 Sandra M. Swain,1,15,16 Norman Wolmark1,17
Abstract
We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic
stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted
therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic complete response
was comparable with other chemotherapy regimens and the high recurrence-free survival and overall survival
are of interest in these high-risk populations.
Background: The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and
bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally
advanced breast cancer (LABC) or pathologic stage 3 breast cancer (PS3BC). Patients and Methods: Patients
received every 3 week treatment with 4 cycles of EC (90/600 mg/m2) followed by 4 cycles of docetaxel (100 mg/m2).
Targeted therapy with standard-dose trastuzumab with bevacizumab 15 mg/kg was given for a total of 1 year.
Coprimary end points were (1) rate of cardiac events (CEs) in all patients deﬁned as clinical congestive heart failure
with a signiﬁcant decrease in left ventricular ejection fraction or cardiac deaths; and (2) pathologic complete response
(pCR) in breast and nodes in the neoadjuvant cohort. An independent cardiac review panel determined whether criteria
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for a CE were met. Results: A total of 105 patients were accrued, 76 with LABC treated with neoadjuvant therapy and
29 with PS3BC treated with adjuvant therapy. Median follow-up was 59.2 months. Among 99 evaluable patients for
cardiac safety, 4 (4%; 95% conﬁdence interval [CI], 1.1%-10.0%) met CE criteria. The pCR percentage in LABC
patients was 46% (95% CI, 34%-59%). Five-year recurrence-free survival (RFS) and overall survival (OS) for all patients was 79.9% and 90.8%, respectively. Conclusion: The regimen met predeﬁned criteria for activity of interest with
an acceptable rate of CEs. Although the pCR percentage was comparable with chemotherapy regimens with trastuzumab alone the high RFS and OS are of interest in these high-risk populations.
Clinical Breast Cancer, Vol. 17, No. 1, 48-54 ª 2016 Elsevier Inc. All rights reserved.
Keywords: Neoadjuvant chemotherapy

Introduction

Patients and Methods

Results from 4 large adjuvant trials showed that incorporating
trastuzumab into standard adjuvant chemotherapy regimens provided substantial improvements in outcomes for women with
HER2-positive breast cancer.1-5 Despite these impressive results,
some patients will develop recurrences after trastuzumab-based
adjuvant therapy, so efforts to identify more effective regimens are
appropriate.
Preclinical data show that increased expression of vascular
endothelial growth factor (VEGF) is associated with HER2 overexpression and occurs downstream of the activated HER2 signaling
pathway.6,7
In HER2-overexpressing xenografts treatment with bevacizumab,
a humanized monoclonal antibody directed at VEGF, and trastuzumab results in a signiﬁcantly greater reduction in tumor volume
than with either treatment alone.8 A correlative study that evaluated
specimens from an adjuvant trial of chemotherapy regimens showed
that women with HER2-positive breast cancers were more likely to
express high levels of VEGF than their HER2-negative counterparts. Women whose tumors contained high levels of HER2 and
VEGF had the worst clinical outcome of any subgroup.9
The combination of trastuzumab and bevacizumab was shown to
be feasible in a phase I study.10 A phase II study of the combination
as ﬁrst-line treatment in women with HER2-positive advanced
breast cancer showed an objective clinical response of 48%, median
time to progression of 7.1 months, and median overall survival (OS)
of 43.8 months.11
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) Foundation FB-5 was a phase II study that evaluated the
safety of incorporating bevacizumab into a standard neoadjuvant/
adjuvant regimen of sequential anthracycline with cyclophosphamide treatment followed by docetaxel with trastuzumab. The primary safety aim was to determine the cardiac safety of dual
antibodies administered with chemotherapy. The primary efﬁcacy
aim was to evaluate the activity of the regimen as neoadjuvant
therapy for locally advanced breast cancer (LABC) by assessing
pathologic complete response (pCR) in the breast and nodes. The
secondary end points were to evaluate 5-year recurrence-free survival
(RFS) and OS, noncardiac toxicities for all patients, and pCR for
breast cancer patients, clinical complete response (cCR), and surgical complications in patients who received neoadjuvant therapy.
All authors had full access to the data in the study; Dr
Buyse and Celine Mauquoi take responsibility for the data
analyses.

Patient Eligibility and Entry Procedures
Women who presented with clinical stage IIIA, IIIB, or IIIC
invasive primary HER2-positive breast cancer diagnosed using core
or limited incisional biopsy were eligible to receive neoadjuvant
therapy in cohort A.
The primary breast tumor had to measure 2.0 cm in clinical
examination unless inﬂammatory breast cancer was present. Women
with resected pN2 (4-9 nodes) or pN3 (10 nodes) breast cancer
comprised cohort B. Patients were required to have an Eastern
Cooperative Oncology Group performance status of 0 or 1, and
adequate bone marrow, renal, and hepatic functions. The left ventricular ejection fraction (LVEF) assessed using echocardiogram
(multigated acquisition (MUGA) scan could be substituted on the
basis of institutional preference) before study entry had to be 55%,
regardless of the institution’s lower limit of normal. Patients with
active cardiac disease, Grade 2 peripheral neuropathy, or metastatic
disease, were ineligible. The study was approved by local institutional
review boards in accordance with assurances ﬁled with and approved
by the Department of Health and Human Services. Patients were
required to give written consent to enter the study.

Treatment
Chemotherapy in both cohorts consisted of epirubicin 90 mg/m2
intravenously (I.V.) and cyclophosphamide 600 mg/m2 I.V. (EC)
on day 1 every 21 days for 4 cycles followed by docetaxel 100 mg/
m2 I.V. on day 1 every 21 days for 4 cycles supported by pegﬁlgrastim 6 mg subcutaneous on day 2 or 3 after docetaxel treatment.
Patients received weekly trastuzumab (ﬁrst dose, 4 mg/kg I.V. and
subsequent doses 2 mg/kg I.V.) concurrently with docetaxel. After
completion of docetaxel treatment, patients received trastuzumab 6
mg/kg every 21 days to complete a year of trastuzumab treatment.
In cohort A, bevacizumab 15 mg/kg was initiated with the last
cycle of EC and administered every 3 weeks with the ﬁrst 3 cycles of
docetaxel, held for surgery, then resumed postoperatively and
administered with trastuzumab for a year. In cohort B, bevacizumab
was initiated with the ﬁrst cycle of docetaxel at 15 mg/kg every 3
weeks and administered with trastuzumab for a year.
Patients who received neoadjuvant therapy underwent lumpectomy or mastectomy after recovery from chemotherapy. Patients
who received adjuvant therapy were eligible after mastectomy or
lumpectomy. Breast reconstruction with implants and use of tissue
expanders was prohibited with bevacizumab treatment and for at
least 3 months after the last dose. It was recommended that breast
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reconstruction be delayed for at least 6 months after completion of
bevacizumab treatment.
Patients with hormone receptor-positive tumors were to receive
endocrine therapy for a minimum of 5 years. Radiotherapy to the
chest wall was required when postmastectomy microscopic margins
were positive and otherwise was at investigator discretion along with
regional node radiotherapy. Whole-breast radiotherapy and regional
nodal radiotherapy were recommended for patients who had
undergone a lumpectomy. Partial breast radiotherapy was prohibited. Evaluation of LVEF using echocardiogram (assessment
using MUGA scan was permitted) was performed at baseline, after
EC (before docetaxel), approximately 6 months from study entry,
and at 9, 12, 15, and 18 months after study entry. All symptoms
suggestive of possible congestive heart failure (CHF) were reported
within 14 days. Source documents were reviewed by an independent cardiac review panel consisting of 2 cardiologists who independently determined whether criteria for a cardiac event (CE) were
met. If one cardiologist considered the case to be a CE, the case was
considered an event. During 5 years of follow-up, at each visit,
speciﬁc data were collected for Grades 2 to 5 left ventricular systolic
dysfunction and Grades 2 to 5 cardiac ischemia/infarction.
The National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0 was used to grade the severity of
adverse events.

documented etiology). CEs were analyzed on the basis of review by
a cardiac advisory panel.
The study was designed with a 2-stage optimum design.12 The
overall sample size of the trial was chosen to reject, with high probability (0.99), a regimen having a true CE rate >11% and to accept,
with high probability (0.99), a regimen having a true CE rate 1%.
A sample size of a total of 100 evaluable patients in cohorts A and B
was needed to deﬁne the primary safety end point in the trial. All
patients who received any treatment with trastuzumab and bevacizumab were considered evaluable. Assuming for 5% nonevaluable
patients, a total of 105 patients were entered in the trial.
The efﬁcacy primary end point was the pCR rate in the breast
and axillary lymph nodes in the evaluable patients in cohort A. The
decision rule stated that the regimen would be considered worthy of
further investigation if this rate reached 25%.
After study therapy was completed, patients had follow-up visits
every 6 months through year 5 from study entry. The following
secondary end points were analyzed with a descriptive intent
only: toxicities, RFS and OS for evaluable patients in cohorts A and
B, and pCR in breast, cCR, and surgical complications for evaluable
patients in cohort A.
The proportions were estimated with their 2-sided exact 95%
conﬁdence interval (CI). The 5-year RFS and OS were estimated
using the KaplaneMeier method.
Adverse events were analyzed according to treatment regimen.

Tumor Assessment and Evaluation of Response (Cohort A)
Pathologic complete response in the breast and lymph nodes was
deﬁned as no histologic evidence of invasive tumor cells in the
surgical breast specimen, axillary nodes, or sentinel lymph nodes
identiﬁed after preoperative chemotherapy. Specimens in which
only noninvasive cancer was found were also classiﬁed as pCR.
Assessment of pCR was made by institutional pathologists without
central review.
Clinical tumor measurement by physical examination was
required before study entry to determine eligibility. Protocolrequired tumor assessments by physical examination were
performed between EC and docetaxel treatment and after the last
cycle of docetaxel to determine the presence or absence of cCR,
deﬁned as the disappearance of all lesions with no evidence of
progressive disease.
Recurrence-free survival was deﬁned as the time from the ﬁrst
dose of EC therapy until the ﬁrst date of recurrence (ipsilateral or
regional invasive breast cancer recurrence or distant recurrence) or
the date of death from any cause in evaluable patients who were
rendered free of disease with surgery. Patients in whom disease had
not recurred or had not died were censored at their last date of
assessment. OS in evaluable patients was measured from the ﬁrst
dose of study therapy until the date of death from any cause.
Patients who had not died were censored at their last contact date.

Statistical Methods
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The primary cardiac safety end point was the rate of overall CEs
in cohorts A and B. CEs were deﬁned as New York Heart Association class III/IV CHF with either a decrease in LVEF to <50% or
a decrease from baseline LVEF of >10 percentage points to 50% to
54%, and cardiac deaths (death due to CHF, myocardial infarction,
documented primary arrhythmia, or sudden death without
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Results
Patient Population and Tumor Characteristics
From April 2007 to May 2009, 105 women were accrued, 76 in
cohort A and 29 in cohort B. The evaluable population for the
cardiac safety analysis consisted of 99 patients, because 6 of the 76
patients in cohort A did not initiate docetaxel-based therapy (THB).
Seventy patients were evaluable for the primary efﬁcacy end point of
pCR in breast and nodes. These 70 patients and all of the 29
patients in cohort B were evaluable for the secondary end points of
RFS and OS. Median follow-up was 59.2 months.
Patient characteristics are provided in Table 1.

Therapy, Compliance, and Adverse Events
Four cycles of EC were completed in 104 (99%) patients. One
patient had progressive disease after 3 cycles of EC in cohort A
(Figure 1) and was removed from the study. Five additional patients in
cohort A did not start THB: 4 for side effects/complications and 1 for
disease progression/treatment failure. Four cycles of THB were
completed in 93 of the 99 patients who began THB. Five did not
complete THB because of side effects/complications, and 1 for
withdrawal/patient refusal. Two patients who did not complete THB
resumed postchemotherapy bevacizumab and trastuzumab treatment. Two patients in cohort A, who completed THB, discontinued
treatment after surgery because of side effects/complications.
After THB, 93 patients continued trastuzumab treatment. Of
these 93 patients 14 received 1 to 6 doses, 6 received 7 to 9 doses,
and 73 received 10 doses. Postchemotherapy bevacizumab
treatment was continued in 79 patients: 24 patients received 1 to 6
doses, 9 patients received 7 to 9 doses, and 46 patients received 10
doses. Postchemotherapy bevacizumab was discontinued because of
side effects/complications (26 patients), disease progression/

John W. Smith II et al
Table 1 Demographic and Tumor Characteristics of Patients
in National Surgical Adjuvant Breast and Bowel
Project (NSABP) FB-5
Characteristic

n (%)

Race
White

91 (87)

Black or African American

13 (12)

Asian

1 (1)

Age, Years
<50

49 (47)

50-59

35 (33)

>59

21 (20)

Clinical Stage, Cohort A
IIIA

38 (50)

IIIB

26 (34)

IIIC

12 (16)

Resected Stage III, Cohort B
pN2

14 (48)

pN3

15 (52)

Clinical Evidence of IBCa, Cohort A
Yes

19 (25)

No

57 (75)

Hormone Receptor Status (ER, PR)
Either positive

62 (59)

Both negative

43 (41)

The sixth edition of the American Joint Committee on Staging was used.
Abbreviations: ER ¼ estrogen receptor; IBC ¼ inﬂammatory breast cancer; PR ¼ progesterone
receptor.
a
IBC (T4d) included in IIIB unless N3 nodes present.

treatment failure (4 patients), patient preference (1 patient), and
other reasons (4 patients).
Of the 76 patients in cohort A, 74 were rendered disease-free
with surgery. Two patients were unable to undergo surgery: 1 for
disease progression/treatment failure and 1 for side effects/complications. Both occurred during EC treatment before initiation of
docetaxel and targeted therapies and the patients were removed
from the study per the investigator.
Whole-breast/chest wall and regional lymph node radiotherapy
was administered to 89 (85%) of the 105 patients entered. Six
additional patients had whole-breast/chest wall radiotherapy
without regional lymph node radiotherapy.

Toxicity
Cardiac Toxicity. Among the 99 patients evaluable for cardiac
safety, 4 (4%; 95% CI, 1.11-10.02) met criteria for a CE (4 CHFs
and no cardiac deaths). On the most recent evaluations of LVEF
measurements, 2 of the 4 patients had recovered LVEF to at least
50%. One patient’s ejection fraction remained at 23% at the
18-month evaluation. The other patient’s ejection fraction
improved to >45%.
Grade 2 and 3 LVEF systolic dysfunction was reported in 14
(14%) and 4 (4%) patients, respectively. Mean LVEF values at
baseline and during the treatment and early follow-up period are
shown in Figure 2.

Overall Toxicity. Selected Grade 2 to 4 adverse events during EC
therapy are provided in Supplemental Table 2. Additional important toxicities in <10% of patients were Grade 3 febrile neutropenia
(3%) and Grade 2 left systolic ventricular dysfunction (2%).
Grade 2 to 4 adverse events during THB are listed in Supplemental
Table 2. Grade 2 and 3 fatigue occurred in 37% and 13%, respectively. Mucositis (functional/symptomatic) was also common with
Grade 2 in 30% and Grade 3 in 4% of patients. Other important
toxicities were Grade 2 and 3 hypertension (8% and 7%, respectively),
Grade 2 and 3 left systolic ventricular dysfunction (5% and 1%,
respectively), and Grade 3 febrile neutropenia (3%).
Grade 2 to 4 adverse events during targeted therapy alone are
provided in Supplemental Table 2. Important Grade 2 and 3 toxicities were, respectively, fatigue (26% and 5%), hypertension (22%
and 12%), and joint pain (15% and 1%). Grade 2 left ventricular
systolic dysfunction was reported in 8 patients (9%).
Surgical complications for cohort A are provided in Supplemental
Table 1 in the online version.

Clinical and Pathologic Responses to Preoperative
Therapy (Cohort A)
A pCR in the breast and nodes was documented in 32 of the 69
patients (46%; 95% CI, 34.3-58.8) who initiated bevacizumab and
trastuzumab treatment and for whom axillary nodal status was
reported. No lymph nodes were identiﬁed in an axillary dissection of 1
patient, so pCR rate in the breast could be assessed in 70 patients and
was 51% (36 of 70; 95% CI, 39.2-63.6). Among patients with hormone receptor-negative breast cancer the pCR rate in breast and nodes
was 59% (19 of 31 patients) and was 34% (13 of 38) in patients with
receptor-positive disease. The pCR for breast and nodes for patients
with inﬂammatory breast cancer was 50% (9 of 18).
The cCR on the basis of investigator assessment (using physical
examination) after EC therapy was 17% (12 of 70; 95% CI, 9.2-28)
and 61% (43 of 70 patients; 95% CI, 49-72.8) after THB.

Recurrence-Free Survival and OS
Among the 99 evaluable patients in both cohorts the 5-year RFS
was 79.9% (95% CI, 70.0-86.8; Figure 3) and 5-year OS was
90.8% (95% CI, 83.0-95.1; Figure 3). The 5-year RFS for the
evaluable patients in cohort A, all of whom were rendered free of
disease at surgery, was 76% (95% CI, 63.5-84.7) and was 89.7%
(95% CI, 71.2-96.5) for cohort B. The 5-year OS for cohort A and
B was 86.9% (95% CI, 76.3-93.0) and 100%, respectively
(Figure 3). Five-year RFS and OS for cohort A was 74.4% and
80.5% for the estrogen receptor (ER)- and progesterone receptor
(PR)-negative subset and 77.3% and 92.1% for the ER- or PRpositive group, respectively, and for cohort B was 75% and 100%
for ER- and PR-negative breast cancer and 95.2% and 100% for the
ER- or PR-positive group, respectively (see Supplemental Figure 1
in the online version). The 5-year RFS and OS for patients with
inﬂammatory breast cancer were 65.7% and 77.8%, respectively, as
shown in Supplemental Figure 2 in the online version.

Discussion
In the NSABP FB-5 study, the combination of bevacizumab with a
regimen of EC followed by docetaxel/trastuzumab did not increase the
expected rate of cardiac toxicity, because the 4% incidence of severe CEs
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Figure 1 Consolidated Standards of Reporting Trials Diagram. (A) Cohort A: Neoadjuvant Therapy; (B) Cohort B: Adjuvant Therapy

Abbreviations: EC ¼ epirubicin with cyclophosphamide therapy; TF ¼ treatment failure; THB ¼ docetaxel with trastuzumab with bevacizumab therapy.
a
Bevacizumab given with ec cycle 4 only; bBevacizumab given with initial 3 cycles of thb; c74 Patients had surgery including patients who discontinued therapy prior to surgery.

was similar to that reported in NSABP B-31.13 Additionally, there were
no late CEs with 5 years of follow-up on the basis of speciﬁc queries on the
follow-up form. The safety proﬁle of bevacizumab used in combination
with the study regimen was also consistent with the known toxicities of
the chemotherapy and targeted agents. In the neoadjuvant cohort, the
regimen met prespeciﬁed criteria for activity of interest with a pCR rate in
the breast and nodes of 46% in HER2-positive LABC. In triple-positive

LABC, the pCR for breast and nodes was 34% and was 59% in those
who were hormone receptor-negative. Secondary efﬁcacy end points of
RFS and OS were notable in this high-risk patient population. In the
evaluable patients who received neoadjuvant treatment, the 5-year RFS
and OS were 76% and 86.9%, respectively. In the hormone receptornegative patients 5-year RFS and OS were 74.4% and 80.5%, respectively, and in the triple positive group were 77.3% and 92.1%,

Figure 2 Mean Left Ventricular Ejection Fraction (LVEF) Over Time in National Surgical Adjuvant Breast and Bowel Project (NSABP)
FB-5

Abbreviations: EC ¼ epirubicin plus cyclophosphamide; THB ¼ docetaxel with trastuzumab with bevacizumab therapy.
Six months after study entry includes for cohort a, after surgery, and for cohort b, after the last dose of docetaxel.

52

-

Clinical Breast Cancer February 2017

John W. Smith II et al
Figure 3 (A) Recurrence-Free Survival and (B) Overall Survival for Combined Cohorts A and B in National Surgical Adjuvant Breast and
Bowel Project (NSABP) FB-5. (C) Recurrence-Free Survival and (D) Overall Survival in Evaluable Patients in Cohorts A and B
in NSABP FB-5

respectively. Five-year RFS and OS were even more striking in the 29
patients who received adjuvant therapy and presented with N2 or N3
disease (89.7% and 100%, respectively), compared with the 76% 5-year
OS in similar patients in NSABP B-31 who were treated with adjuvant
chemotherapy and trastuzumab.
The NeOAdjuvant Herceptin (NOAH) trial14,15 evaluated the
combination of trastuzumab with neoadjuvant chemotherapy in a
similar population of women with HER2-positive locally advanced
or inﬂammatory breast cancer, and also has reported pCR and
long-term outcomes. Because NOAH reported pCR, event-free
survival, and OS on the basis of all 117 patients randomly
assigned to the trastuzumab and chemotherapy group, we also
determined the pCR for breast and node rate and the 5-year OS
for all 76 patients in cohort A (see Supplemental Figure 3 in the
online version). The pCR rates in breast and node in the trials
were similar: 38% for NOAH and 45% in all 76 patients who
received neoadjuvant therapy in FB-5. The 5-year OS rate among
all of the patients who received neoadjuvant treatment in FB-5

(84%) was somewhat higher than in NOAH (74%). Of interest,
when the 5-year OS was compared according to hormone receptor
status, although there was no difference among ER- and
PR-negative patients between FB-5 and NOAH (76% vs. 78%), a
striking difference was present in the triple-positive patients: 90%
for FB-5 versus 65% for NOAH.
It is difﬁcult to explain the favorable long-term outcomes in FB-5
in light of the negative results of the Bevacizumab with Trastuzumab Adjuvant Therapy in HER2þ Breast Cancer (BETH)16 trial,
which evaluated the combination of bevacizumab with standard
adjuvant chemotherapy regimens in combination with trastuzumab.
Most patients in BETH received TCH (taxotere carboplatin herceptin) with or without bevacizumab and only 21% had N2 or N3
disease. Patients who received chemotherapy and trastuzumab had a
3-year invasive disease-free survival of 90%, so improvements
shown with the combination of bevacizumab in the relatively lowrisk population entered into BETH might have precluded observation of some beneﬁt in high-risk patients.
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Conclusion
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Clinical Practice Points
 Neoadjuvant studies that assess pCRs allow for rapid evaluation

of the beneﬁt of new treatments.
 The safety proﬁle of bevacizumab combined with this regimen

was consistent with the known toxicities of chemotherapy and
targeted agents.
 In the neoadjuvant cohort, the regimen met prespeciﬁed criteria
for activity of interest with a pCR rate in the breast and nodes of
46% in HER2-positive LABC.
 Favorable long-term outcomes were notable in this high-risk
patient population.
 Because of the activity and safety of pertuzumab and trastuzumab combined with chemotherapy, it is difﬁcult to justify
further evaluation of bevacizumab administered with trastuzumab in this setting, despite the encouraging ﬁndings in this trial.
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Supplemental Figure 1 (A) Recurrence-Free Survival and (B) Overall Survival According to Hormone Receptor (HR) Positive and
Negative Breast Cancer in National Surgical Adjuvant Breast and Bowel Project (NSABP) FB-5

Supplemental Figure 2 (A) Recurrence-Free Survival and (B) Overall Survival of Inﬂammatory and Noninﬂammatory Breast Cancer in
National Surgical Adjuvant Breast and Bowel Project (NSABP) FB-5
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Supplemental Figure 3 All Patients Entered in Study for National Surgical Adjuvant Breast and Bowel Project (NSABP) FB-5. Overall
Survival (A) for Combined Cohorts A and B; and (B) Cohorts A and B for NSABP FB-5

Supplemental Table 1 Surgical Complications of Patients in
National Surgical Adjuvant Breast and
Bowel Project (NSABP) FB-5 for Cohort
A (Total Patients With at Least 1
Complication)
CTCAE Version 3.0 Grade
(n [ 74), n (%)
Toxicity
One or More Complications
Seromab
Wound Complications, Noninfectiousc
Infection With Normal ANC or Grade
1 or 2 Neutrophils
Hematomad

Grade 2
21
13
4
5

(28)
(18)
(5)
(7)

2 (3)

a

Grade 3
11
3
3
8

(15)a
(4)
(4)
(11)
0

Abbreviations: ANC ¼ absolute neutrophil count; CTCAE ¼ Common Terminology Criteria for
Adverse Events.
a
More than 1 complication could occur in 1 patient.
b
Grade 2, simple aspiration; Grade 3, interventional radiology or surgical intervention.
c
Grade 2, incisional separation >25%; Grade 3, fascial disruption or primary wound closure.
d
Grade 2, simple aspiration; Grade 3, interventional radiology or surgical intervention.
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Supplemental Table 2 Commonly Observed Grade 2-4
Adverse Events that Occurred in at
Least 10% of Patients and Adverse
Events of Special Interest According to
CTCAE Version 3.0 in National Surgical
Adjuvant Breast and Bowel Project
(NSABP) FB-5
Adverse Event

Grade 2

Grade 3

Grade 4

Fatigue
a

Febrile neutropenia
Headache
LVSDa

Grade 3

Nail changes

13 (14)

1 (1)

0

3 (3)

0

0

Proteinuria

Grade 4

Rash

10 (11)

0

0

Sensory neuropathy

13 (14)

1 (1)

0

Joint

14 (15)

1 (1)

0

1 (1)

0

34 (32)

3 (3)

0

Bone

12 (13)

0

0

Headache

8 (9)

2 (2)

0

0

3 (3)

0

13 (12)

2 (2)

0

2 (2)

0

0

25 (24)

2 (2)

0

Neutrophils

13 (12)

8 (8)

2 (2)

Vomiting

Grade 2

11 (10)

Nausea
Thrombosis/embolisma

Adverse Event

Pain

With EC Treatment (n [ 105)
Dehydration

Supplemental Table 2 Continued

0

1 (1)

0

17 (16)

2 (2)

0

Data are presented as n (%).
Abbreviations: CTCAE ¼ Common Terminology Criteria for Adverse Events; EC ¼ epirubicin
with cyclophosphamide; GI ¼ gastrointestinal; LVSD ¼ left ventricular systolic dysfunction;
THB ¼ docetaxel with trastuzumab and bevacizumab.
a
Toxicity <10% (listed because of clinical signiﬁcance).
b
One patient with Grade 2 left ventricular ejection fraction (LVEF) had an asymptomatic
decrease in LVEF during THB treatment. LVEF recovered and the patient resumed targeted
therapy. She had a decrease in LVEF as a second event during targeted therapy.

With THB Treatment (n [ 99)
Diarrhea

16 (16)

2 (2)

0

Fatigue

37 (37)

13 (13)

0

0

3 (3)

0

8 (8)

2 (2)

0

GI

1 (1)

1 (1)

0

Nose

5 (5)

0

0

Hypertension

8 (8)

7 (7)

0

LVSDa

5 (5)b

1 (1)

0

Functional/symptomatic

30 (30)

4 (4)

0

Clinical examination

11 (11)

2 (2)

0

Nail changes

12 (12)

0

0

Nausea

14 (14)

0

0

Febrile neutropeniaa
Hand-foot
Hemorrhage

Mucositis

Rash

12 (12)

1 (1)

0

Sensory neuropathy

11 (11)

5 (5)

0

Taste alteration

14 (14)

0

0

0

1 (1)

0

10 (10)

1 (1)

0

9 (9)

2 (2)

0

Thrombosis/embolisma
Vomiting
Watery eye
Pain
Bone

24 (24)

7 (7)

0

Muscle

23 (23)

7 (7)

0

Joint

17 (17)

3 (3)

1 (1)

Headache

8 (8)

1 (1)

1 (1)

During Targeted Therapy Alone
(n [ 93)
Depression
Fatigue

8 (9)

1 (1)

1 (1)

24 (26)

5 (5)

0

1 (1)

0

0

Hemorrhage
GI
Hot ﬂashes

13 (14)

0

0

Hypertension

20 (22)

11 (12)

1 (1)

8 (9)b

0

0

LVSDa
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